PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wang, Xin ^a   Jung, Youn Sang ^a   Jun, Sohee ^a   Lee, Sunhye ^a   Wang, Wenqi ^a   Schneider, Andrea ^a   Sun Oh, Young ^a   Lin, Steven H ^a   Park, Bum Joon ^b   Chen, Junjie ^a   Keyomarsi, Khandan ^a   Park, Jae Il ^a,c,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Pusan National University   (South Korea)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LUMINESPIB; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; ISOXAZOLE DERIVATIVE; KIAA0101 PROTEIN, HUMAN; PAF PROTEIN, MOUSE; RESORCINOL DERIVATIVE;

CANCER; CELLS AND CELL COMPONENTS; DRUG DEVELOPMENT; GENE EXPRESSION; GROWTH RATE; HETEROGENEITY; IMMUNE RESPONSE; SENSORY SYSTEM; TUMOR;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; BREAST HYPERPLASIA; CANCER CELL; CANCER STEM CELL; CELL GROWTH; CELL PLASTICITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPERPLASIA; PROTEIN EXPRESSION; STEM CELL; WNT SIGNALING PATHWAY; ANIMAL; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOBLOTTING; KAPLAN MEIER METHOD; LUNG CARCINOMA; MCF-7 CELL LINE; METABOLISM; MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC ANIMAL; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; UDDER;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PLASTICITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYPERPLASIA; IMMUNOBLOTTING; ISOXAZOLES; KAPLAN-MEIER ESTIMATE; MAMMARY GLANDS, ANIMAL; MCF-7 CELLS; MICE; NEOPLASTIC STEM CELLS; RESORCINOLS; TUMOR STEM CELL ASSAY; WNT SIGNALING PATHWAY;

EID: 84957575532     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10633     Document Type: Article

References (69)

1. Weissman, I. L., Anderson, D. J. & Gage, F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 17, 387-403 (2001).
2. Dezawa, M. et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309, 314-317 (2005).
3. Jackson, K. A., Mi, T. & Goodell, M. A. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc. Natl Acad. Sci. USA 96, 14482-14486 (1999).
4. Cobaleda, C., Jochum, W. & Busslinger, M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449, 473-477 (2007).
5. Heyworth, C., Pearson, S., May, G. & Enver, T. Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells. EMBO J. 21, 3770-3781 (2002).
6. Caiazzo, M. et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224-227 (2011).
7. Pang, Z. P. et al. Induction of human neuronal cells by defined transcription factors. Nature 476, 220-223 (2011).
8. Sekiya, S. & Suzuki, A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475, 390-393 (2011).
9. Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41-46 (2004).
10. Thorel, F. et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464, 1149-1154 (2010).
11. Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455, 627-632 (2008).
12. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
13. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
14. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
15. Yu, P. et al. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 20, 484-489 (2001).
16. Povlsen, L. K. et al. Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat. Cell Biol. 14, 1089-1098 (2012).
17. Jung, H. Y. et al. PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol. Cell 52, 193-205 (2013).
18. Liu, Y. et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 73, 7297-7307 (1999).
19. Jun, S. et al. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep. 5, 314-322 (2013).
20. Wielenga, V. J. et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515-523 (1999).
21. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
22. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
23. Band, V., Zajchowski, D., Kulesa, V. & Sager, R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc. Natl Acad. Sci. USA 87, 463-467 (1990).
24. Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007).
25. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011).
26. Lustig, B. et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol. 22, 1184-1193 (2002).
27. Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108, 5954-5963 (2011).
28. Kolligs, F. T., Hu, G., Dang, C. V. & Fearon, E. R. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell. Biol. 19, 5696-5706 (1999).
29. He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
30. Wong, D. J. et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2, 333-344 (2008).
31. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
32. Jaenisch, R. & Young, R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132, 567-582 (2008).
33. Loh, Y. H. et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38, 431-440 (2006).
34. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317 (2007).
35. Leis, O. et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31, 1354-1365 (2012).
36. Ponti, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511 (2005).
37. Patel, S. A. et al. Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci. Rep. 2, 906 (2012).
38. Fillmore, C. M. & Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25 (2008).
39. Hiyama, E. & Hiyama, K. Telomere and telomerase in stem cells. Br. J. Cancer 96, 1020-1024 (2007).
40. Buczacki, S. J. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65-69 (2013).
41. Jun, S. et al. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep. 5, 314-322 (2013).
42. Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837-1851 (2000).
43. Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012).
44. Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., Parslow, T. & Varmus, H. E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55, 619-625 (1988).
45. Dolled-Filhart, M. et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 66, 5487-5494 (2006).
46. Lin, S. Y. et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA 97, 4262-4266 (2000).
47. Khramtsov, A. I. et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176, 2911-2920 (2010).
48. Geyer, F. C. et al. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol. 24, 209-231 (2011).
49. Hayes, M. J., Thomas, D., Emmons, A., Giordano, T. J. & Kleer, C. G. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin. Cancer Res. 14, 4038-4044 (2008).
50. Zardawi, S. J., O'Toole, S. A., Sutherland, R. L. & Musgrove, E. A. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol. Histopathol. 24, 385-398 (2009).
51. Shtutman, M. et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA 96, 5522-5527 (1999).
52. Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA 101, 4158-4163 (2004).
53. Kessenbrock, K. et al. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell 13, 300-313 (2013).
54. Zeng, Y. A. & Nusse, R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6, 568-577 (2010).
55. Wang, Y. et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650-1653 (2010).
56. Rosner, A. et al. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am. J. Pathol. 161, 1087-1097 (2002).
57. van Amerongen, R., Bowman, A. N. & Nusse, R. Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 11, 387-400 (2012).
58. Das, B. et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26, 1818-1830 (2008).
59. Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706 (2009).
60. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011).
61. Mortlock, A. A. et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. Med. Chem. 50, 2213-2224 (2007).
62. Tao, Y. et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27, 3244-3255 (2008).
63. Azzariti, A. et al. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br. J. Cancer 104, 769-780 (2011).
64. Lyne, P. D. et al. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 47, 1962-1968 (2004).
65. Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955-2966 (2008).
66. Mitchell, J. B. et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin. Cancer Res. 16, 2076-2084 (2010).
67. Jensen, M. R. et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10, R33 (2008).
68. Amrani, Y. M. et al. The Paf oncogene is essential for hematopoietic stem cell function and development. J. Exp. Med. 208, 1757-1765 (2011).
69. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).